Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.38 |
| ▸ | ARG2 | P78540 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28132469 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2HIF1AFDPSCYP2C9CYP2C19 | |
| SCHEMBL1325186 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2HIF1AFDPSCYP2C9CYP2C19 | |
| SCHEMBL6834107 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2HIF1AFDPSCYP2C9CYP2C19 | |
| SCHEMBL31745420 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2HIF1AFDPSCYP2C9CYP2C19 | |
| SCHEMBL3863998 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2HIF1AFDPSCYP2C9CYP2C19 | |
| SCHEMBL9137764 | 0.75 | FDPS (0.50) | SMN1; SMN2HIF1AFDPSCYP2C9CYP2C19 | |
| SCHEMBL5031234 | 0.74 | HIF1A (0.50) | SMN1; SMN2HIF1ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL29112713 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1AFDPSCYP2C9CYP2C19 | |
| SCHEMBL3736878 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1AFDPSCYP2C9CYP2C19 | |
| SCHEMBL30887346 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1AFDPSCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270429-A1 | PROTEIN-BASED ADHESIVE AND ITS MODIFICATION | PURDUE RESEARCH FOUNDATION (US) | 2025-08-28 | — | — | US | claimed |
| US-12331230-B2 | Protein-based adhesive and its modification | PURDUE RESEARCH FOUNDATION | 2025-06-17 | — | — | US | claimed |
| US-20210207013-A1 | PROTEIN-BASED ADHESIVE AND ITS MODIFICATION | PURDUE RESEARCH FOUNDATION (US) | 2021-07-08 | — | — | US | claimed |
| WO-2020041557-A1 | PROTEIN-BASED ADHESIVE AND ITS MODIFICATION | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | WO | claimed |
| US-20190201349-A1 | CAPSULES AND PARTICLES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-07-04 | — | — | US | claimed |
| WO-2017072759-A1 | CAPSULES AND PARTICLES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-05-04 | — | — | WO | claimed |
| EP-2306192-B1 | Risk Markers For Cardiovascular Disease | CLEVELAND CLINIC FOUNDATION (US) | 2015-10-14 | — | — | EP | claimed |
| US-9005904-B2 | Risk markers for cardiovascular disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2015-04-14 | — | — | US | claimed |
| US-20150037905-A1 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2015-02-05 | — | — | US | claimed |
| US-8722344-B2 | Risk markers for cardiovascular disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2014-05-13 | — | — | US | claimed |
| EP-2306192-A2 | Risk Markers For Cardiovascular Disease | The Cleveland Clinic Foundation (US) | 2011-04-06 | — | — | EP | claimed |
| EP-2268305-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | The Cleveland Clinic Foundation (US) | 2011-01-05 | — | — | EP | claimed |
| US-7781219-B2 | determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample; atherosclerosis | THE CLEVELAND CLINIC FOUNDATION (US) | 2010-08-24 | — | — | US | claimed |
| US-20100183607-A1 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2010-07-22 | — | — | US | claimed |
| WO-2009114875-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-09-17 | — | — | WO | claimed |
| EP-1697746-A4 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | CLEVELAND CLINIC FOUNDATION (US) | 2007-08-29 | — | — | EP | claimed |
| EP-1697746-A2 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | The Cleveland Clinic Foundation (US) | 2006-09-06 | — | — | EP | claimed |
| US-20050239136-A1 | Risk markers for cardiovacular disease | THE CLEVELAND CLINIC FOUNDATION | 2005-10-27 | — | — | US | claimed |
| WO-2005055810-A2 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2005-06-23 | — | — | WO | claimed |
| US-5047344-A | Alteromonas Bacteria To Attract Oyster Larvae | RESEARCH CORPORATION TECHNIQUES, INC. (US) | 1991-09-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201349-A1 | CAPSULES AND PARTICLES AND USES THEREOF | ALG1, LPO, FUT5 | SMN1; SMN2 4359/4885HIF1A 3448/4885FDPS 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.